Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Preliminary Efficacy of CG009301 for Injection in Adult Subjects With Relapsed or Refractory Haematological Malignancies
Conditions
Interventions
CG009301 for Injection
Locations
3
China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The Haematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Start Date
April 17, 2025
Primary Completion Date
December 30, 2027
Completion Date
December 30, 2027
Last Updated
January 16, 2026
NCT06735690
NCT05564390
NCT00131014
NCT03050268
NCT06074666
NCT06973668
Lead Sponsor
Cullgen (Shanghai),Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions